Skip to main content

Table 2 Number of events and hazard ratio (CI 95%), for death and clinical outcomes in matched populations according to treatment status (PP analysis)

From: Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study

Outcomes

Cohort

 

GLP-1 RA N = 12,062 N (%)

SGLT-2i N = 11,470 N (%)

HR (CI95%)

Death

528 (4.4)

555 (4.8)

0.89 (0.79–1.00)

Mace3

690 (5.7)

736 (6.4)

0.88 (0.79–0.98)

Mace4

881 (7.3)

917 (8.0)

0.91 (0.83–1.00)

Myocardial infarction

170 (1.4)

228 (2.0)

0.70 (0.57–0.85)

Stroke

71 (0.6)

82 (0.7)

0.82 (0.60–1.13)

Heart failure

277 (1.7)

238 (2.0)

1.11 (0.93–1.32)

Renal disease

36 (0.3)

11 (0.1)

3.04 (1.60–6.20)

  1. GLP-1RA glucagon-like peptide-1 receptor agonists, SGLT-2i sodium glucose transporter-2 inhibitors;
  2. MACE-3 all cause death, non-fatal myocardial infarction, non-fatal stroke, MACE-4 all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840